News Altimmune, Inc.

Equities

ALT

US02155H2004

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
6.91 ^USD	+0.29%		-13.52%	-38.58%

Apr. 02	Transcript : Altimmune, Inc. - Special Call
Mar. 27	Altimmune Shares Slip Wednesday, After Reporting a Wider Q4 Net Loss and Dropping Prospective Treatment for Hepatitis B	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Transcript : Altimmune, Inc. - Special Call	Apr. 02
Altimmune Shares Slip Wednesday, After Reporting a Wider Q4 Net Loss and Dropping Prospective Treatment for Hepatitis B	Mar. 27	MT
Transcript : Altimmune, Inc., Q4 2023 Earnings Call, Mar 27, 2024	Mar. 27
Altimmune, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 27	CI
Earnings Flash (ALT) ALTIMMUNE Reports Q4 Revenue $37,000	Mar. 27	MT
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 27	AQ
Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023	Mar. 27	CI
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024	Mar. 20	AQ
North American Morning Briefing : Stock Futures -2-	Mar. 19	DJ
Altimmune, Inc.(NasdaqGM:ALT) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
North American Morning Briefing : Inflation Data -2-	Mar. 12	DJ
ROSEN, A LONGSTANDING LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT	Mar. 05	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT	Mar. 03	PR
Drugmakers deepen efforts to tap into booming market for obesity drugs	Feb. 27	RE
Zealand shares surge on liver drug data from Boehringer pact	Feb. 26	RE
Altimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	Feb. 26	BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT	Feb. 24	PR
ROSEN, LEADING INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT	Feb. 16	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT	Feb. 15	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Altimmune, Inc.

Equities

ALT

US02155H2004

Summary

Filters